Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

Phase 1

Withdrawn

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Radiation: TLI
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT06003179

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Letetresgene autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-08-15

Last Posted Date: 2024-10-22

Lead Sponsor: Adaptimmune

Target Recruit Count: 7

Registration Number: NCT05993299

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States

and more 35 locations

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: AML, Adult
Minimal Residual Disease

Interventions: Drug: CD33/CLL1 dual CAR-NK cell
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: super NK cell
Drug: CD33 CAR-NK cell
Drug: Cytarabine

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 102

Registration Number: NCT05987696

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Biological: Aldesleukin
Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Mammogram
Procedure: Multigated Acquisition Scan
Procedure: Ultrasound Imaging

First Posted Date: 2023-08-14

Last Posted Date: 2025-01-01

Lead Sponsor: University of Southern California

Target Recruit Count: 20

Registration Number: NCT05989828

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Neoplasms

Interventions: Biological: Camrelizumab
Procedure: Surgery for harvesting tumor-draining lymph nodes
Drug: Nab-paclitaxel
Drug: Cyclophosphamide
Drug: Gemcitabine
Drug: Fludarabine
Biological: Tumor-draining lymph node-derived lymphocyte (LNL)
Biological: Interleukin-2
Drug: Carboplatin

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 170

Registration Number: NCT05981001

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Neoplasms

Interventions: Procedure: Sentinel Lymph Node Biopsy (SLNB)
Drug: Doxorubicin
Drug: Epirubicin
Drug: Nab-paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Tumor-draining lymph node-derived lymphocyte (LNL)
Biological: Interleukin-2

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 196

Registration Number: NCT05981014

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Phase 1

Recruiting

Conditions: Relapsed or Refractory CD19+ B-cell Lymphoma
Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions: Biological: TBI-2001
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-07-27

Last Posted Date: 2024-08-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 19

Registration Number: NCT05963217

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Azacitidine
Drug: Cytarabine
Drug: Gemtuzumab Ozogamicin
Drug: Daunorubicin Hydrochloride
Drug: Idarubicin Hydrochloride
Drug: Fludarabine Phosphate
Drug: Mitoxantrone Hydrochloride
Drug: Etoposide
Drug: Gilteritinib

First Posted Date: 2023-07-21

Last Posted Date: 2025-01-09

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 70

Registration Number: NCT05955261

Locations: 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

and more 2 locations

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Other: Fludeoxyglucose F-18
Other: Immunotherapy
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-07-18

Last Posted Date: 2024-05-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT05950113

Locations: 🇺🇸
Melanie Ayala Ceja, Los Angeles, California, United States

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Phase 1

Recruiting

Conditions: Relapsed/Refractory B-Cell Lymphoma

Interventions: Drug: FT522
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2023-07-18

Last Posted Date: 2024-07-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 166

Registration Number: NCT05950334

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy